Mirati Therapeutics, Inc. (NASDAQ:MRTX) was founded in 1995 and is headquartered in San Diego, California, with 63 full-time employees. It is a clinical-stage biopharmaceutical company specializing in anti-cancer drugs and their product lines.
Mirati Therapeutics, Inc. (MRTX):
Mirati Therapeutics is a clinical-stage oncology company that develops product candidates in the United States to address cancer genetic and immune promoter problems.
Mirati Therapeutics has participated in the development of a spectrum-selective kinase inhibitor Sitravatinib, which is in the phase II clinical phase for the treatment of non-small cell lung cancer (NCSLC); and phase Ib for the treatment of the genetic alteration of Casitas B-line lymphoma in patients with NCSLC Clinical trials; and KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients and other cancers.
Mirati Therapeutics has also developed mocetinostat, a selective class I and class IV histone deacetylase inhibitor for oral research, which has been combined with Ourvalumab to complete a phase II clinical trial for the treatment of NSCLC.
Mirati Therapeutics signed a cooperation and licensing agreement with BeiGene, Ltd. to develop, produce and commercialize sitravatinib.
Mirati Therapeutics’ clinical stage product candidates include:
- MGCD265 , a multi-target kinase inhibitor, is currently in the Ib clinical development trial stage for the treatment of non-small cell lung cancer and other solid tumors, such as cancer found in the stomach and squamous cell carcinoma of the head and neck;
- MGCD516 , a kinase inhibitor, is currently in the Ib clinical development stage for the treatment of solid tumors with emphasis on genetic changes.
- Mocetinostat , an oral bioavailable histone deacetylase inhibitor, is currently in phase II clinical trials for patients with bladder cancer, myelodysplastic syndrome and non-Hodgkin’s lymphoma, mainly diffuse large B Cell lymphoma and follicular lymphoma.
Mirati Therapeutics has reached a cooperation agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore their partnership with QIAGEN NV for the development of MGCD265 as a companion diagnostic platform to develop and commercialize a companion diagnostic test to guide The use of glesatinib (MGCD265) and a targeted therapy for non-small cell lung cancer are under development.